MarketBeat
21 Nov 2026, 04:12 UTC · 1h ago
Incyte Bets on Drug Pipeline and Deals for Growth After Jakafi Exclusivity Ends
Impact · against what's priced in
Incyte's updated guidance on its non-Jakafi portfolio and povorcitinib timeline provides concrete evidence for the bull case the market has previously ignored. Specifically, the projected $3-4bn baseline by 2030 and significant M&A firepower directly challenge the assumption that the company is destined for low single-digit expansion.
- INCY+0.50
Challenges what's priced in
- The price assumes





